Next-Generation Sequencing (NGS) Market Report

Global Next-Generation Sequencing Market Size

In 2024, the global next-generation sequencing (NGS) market was valued at USD 6.06 billion and is forecasted to grow to USD 28.26 billion by 2033, at a CAGR of 18.66%.

Next-Generation Sequencing (NGS) represents a transformative leap in genomic science, enabling the rapid, high-throughput decoding of DNA and RNA at a scale and speed unattainable with traditional Sanger sequencing. Unlike its predecessor, NGS allows parallel sequencing of millions of genetic fragments, facilitating comprehensive analysis of entire genomes, exomes, or transcriptomes within days. This technology has redefined biomedical research, clinical diagnostics, and personalized medicine by unlocking granular insights into genetic variation, gene expression, and microbial composition. The integration of NGS in national health initiatives is evident in the United Kingdom’s 100,000 Genomes Project, which successfully linked genomic data to patient records, leading to diagnoses for previously undetectable rare diseases. In agriculture, the International Rice Research Institute utilized NGS to identify drought-resistant gene markers in over 3,000 rice varieties, accelerating crop improvement programs across Southeast Asia. Furthermore, these applications illustrate that NGS extends beyond sequencing—it is a pivotal engine driving precision health, evolutionary biology, and biosecurity. Its expanding utility across disciplines marks NGS not merely as a laboratory tool but as a cornerstone of 21st-century life sciences innovation.

MARKET DRIVERS

Expansion of Precision Medicine and Genomic-Driven Therapeutics

The ascent of precision medicine has become a principal catalyst for the proliferation of Next-Generation Sequencing, as healthcare systems increasingly adopt genomic profiling to guide therapeutic decisions. In oncology, NGS enables the identification of tumor-specific mutations, allowing clinicians to deploy targeted therapies that improve patient outcomes. In rare disease diagnosis, the Undiagnosed Diseases Network in the United States reported a diagnostic success rate using whole-exome sequencing, drastically reducing the diagnostic odyssey for patients. As regulatory bodies and healthcare providers recognize the cost-effectiveness of early genomic intervention, the demand for scalable, accurate sequencing platforms continues to surge, positioning NGS as an indispensable component of modern therapeutic development and delivery.

Integration of NGS in Public Health and Pathogen Surveillance

The role of Next-Generation Sequencing in infectious disease monitoring has emerged as a critical driver, particularly in the wake of global pandemics and antimicrobial resistance crises. During the SARS-CoV-2 outbreak, NGS enabled real-time tracking of viral evolution, with the global GISAID initiative amassing over 16 million genomic sequences by 2023, allowing scientists to detect variants such as Omicron within days of emergence. In tuberculosis control, the TB-Seq program in South Africa has sequenced a notable number of Mycobacterium tuberculosis isolates, identifying drug-resistant strains and informing public health interventions. Furthermore, in wastewater-based epidemiology, the European Centre for Disease Prevention and Control documented the use of NGS to detect poliovirus resurgence in London and Jerusalem, triggering rapid vaccination campaigns. These applications underscore NGS as a strategic public health infrastructure, transforming reactive medicine into proactive surveillance and reinforcing its indispensability in safeguarding global health security.

MARKET RESTRAINTS

High Operational and Infrastructure Costs in Low- and Middle-Income Countries

The widespread adoption of Next-Generation Sequencing is hindered by substantial financial and logistical barriers, particularly in resource-constrained settings. Like, maintenance, reagent supply chains, and cryogenic storage further escalate operational expenditures. Besides, the requirement for uninterrupted power supply and climate-controlled environments exacerbates deployment challenges. The scarcity of trained bioinformaticians compounds the issue. In Latin America, despite growing research interest. These disparities create a genomic divide, where advanced diagnostics remain concentrated in high-income nations, undermining equitable access to life-saving technologies and constraining global health resilience.

Data Privacy and Ethical Concerns in Genomic Information Handling

The exponential generation of genetic data through NGS has intensified global scrutiny over data governance, consent, and misuse, creating significant ethical and legal impediments to adoption. Genomic information is inherently sensitive, capable of revealing predispositions to diseases, familial relationships, and ancestry, raising concerns about discrimination and unauthorized access. Indigenous populations have voiced particular concern; the Navajo Nation in the U.S. maintains a moratorium on genetic research due to historical exploitation, as affirmed by the Tribal Council. Furthermore, the potential for genomic data to be weaponized in insurance or employment decisions persists; in Japan, a notable share of citizens expressed reluctance to undergo genetic testing due to fears of social stigma. These ethical dilemmas necessitate robust regulatory frameworks, but the absence of harmonized international standards continues to stifle collaboration and public trust, impeding the full realization of NGS’s societal benefits.

MARKET OPPORTUNITIES

Advancement of Single-Cell and Spatial Sequencing Technologies

The emergence of single-cell and spatial transcriptomics represents a frontier in Next-Generation Sequencing, offering unprecedented resolution in understanding cellular heterogeneity and tissue architecture. Unlike bulk sequencing, which averages gene expression across cell populations, single-cell NGS enables the profiling of individual cells, revealing rare cell types and transitional states critical in cancer and developmental biology. As per the Human Cell Atlas initiative, researchers have mapped over 50 million cells across 33 human organs using single-cell RNA sequencing, generating foundational datasets for disease modeling. In immunology, the Parker Institute for Cancer Immunotherapy utilized single-cell NGS to identify tumor-infiltrating lymphocyte subtypes responsible for treatment response, leading to novel checkpoint inhibitor designs. Spatial sequencing, which preserves the geographical context of gene expression within tissue sections, has been adopted in a significant share of major pharmaceutical R&D centers. The technology has enabled breakthroughs in neurodegenerative disease research, with the Allen Institute for Brain Science mapping gene activity in Alzheimer’s-affected brain regions at subcellular resolution. Startups such as 10x Genomics and NanoString have commercialized integrated platforms that combine NGS with imaging, accelerating adoption in academic and clinical labs. With funding from the U.S. BRAIN Initiative and the EU’s Horizon Europe program, spatial genomics is poised to redefine precision pathology, enabling diagnostics that correlate molecular profiles with tissue morphology. This convergence of sequencing and imaging technologies opens transformative pathways in drug discovery and personalized medicine.

Integration of Artificial Intelligence in Genomic Data Interpretation

The fusion of artificial intelligence with Next-Generation Sequencing data analysis is unlocking new dimensions of insight, addressing the bottleneck of interpreting vast and complex genomic datasets. Traditional bioinformatics pipelines often require weeks to annotate variants and predict pathogenicity, but AI-driven platforms can reduce this to hours while improving accuracy. As per the Broad Institute of MIT and Harvard, deep learning models such as DeepVariant have achieved over 99% precision in identifying single-nucleotide variants from NGS data, surpassing conventional algorithms. The UK Biobank has trained machine learning models on NGS and phenotypic data from a notable number of participants, enabling the prediction of polygenic risk scores for heart disease and diabetes. Furthermore, AI is being used to discover non-coding regulatory elements. Companies like Owkin and Tempus are deploying federated learning to train AI models across hospitals without sharing raw data, preserving privacy while enhancing predictive power. This synergy between NGS and AI not only accelerates discovery but also democratizes access to genomic insights, heralding a new era of intelligent, scalable precision medicine.

MARKET CHALLENGES

Standardization and Interoperability of Sequencing Platforms and Data Formats

The lack of universal standards for data generation, storage, and exchange, leading to fragmentation and reproducibility issues across laboratories and clinical settings, is a persistent challenge in the Next-Generation Sequencing market. Different sequencing platforms, such as Illumina, Oxford Nanopore, and PacBio, produce data in proprietary formats with varying error profiles, complicating cross-platform comparison. The absence of standardized bioinformatics pipelines further exacerbates variability. Regulatory bodies struggle to keep pace, while the FDA has issued guidelines for NGS-based tests, enforcement remains inconsistent. In multi-center trials, data integration delays can extend timelines by up to six months, as noted by the International Cancer Genome Consortium. Without cohesive global standards, the promise of interoperable genomic medicine remains fragmented, undermining collaboration, regulatory approval, and clinical implementation.

Scalability of Bioinformatics Workforce and Computational Infrastructure

The exponential growth of genomic data has outpaced the availability of skilled bioinformaticians and high-performance computing resources, creating a critical bottleneck in the utility of Next-Generation Sequencing. Each human genome generates approximately 200 gigabytes of raw data, requiring sophisticated computational tools for alignment, variant calling, and interpretation. Cloud computing offers partial relief, but data transfer and storage costs remain prohibitive. Moreover, real-time clinical applications, such as rapid neonatal diagnosis, require immediate processing, yet most hospitals lack on-site computational clusters. Training programs are expanding, but the interdisciplinary nature of bioinformatics, spanning biology, computer science, and statistics, creates steep learning curves. Without parallel investment in human capital and digital infrastructure, the scalability of NGS will remain constrained, limiting its transition from research tool to routine clinical practice.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Product Insights

The consumables segment dominated the global Next-Generation Sequencing market by capturing 48.6% of total revenue in 2024. This segment’s dominance is primarily driven by the consumptive nature of NGS workflows, where each sequencing run requires fresh reagents and disposable components. Unlike capital-intensive platforms, consumables, including sequencing kits, reagents, primers, and flow cells, are subject to recurring demand, creating a consistent revenue stream for suppliers. In high-throughput environments such as population genomics projects, the scale intensifies. Additionally, the sensitivity of NGS to reagent quality necessitates brand loyalty, with institutions preferring original manufacturer kits to ensure data accuracy. Furthermore, the rise of single-cell and long-read sequencing has introduced specialized, high-cost consumables, such as microfluidic chips and barcoding reagents, which retail at up to five times the price of standard kits, as noted by the Journal of Laboratory Automation. These interdependent factors—recurring usage, regulatory compliance, and technological complexity—collectively sustain the consumables segment as the financial backbone of the NGS ecosystem.

The bioinformatics segment is emerging as the fastest-growing component of the Next-Generation Sequencing market and is projected to expand at a CAGR of 15.6% from 2025 to 2033. This acceleration is fueled by the escalating complexity of genomic data and the urgent need for advanced analytical tools to extract clinically and scientifically meaningful insights. A single whole-genome sequencing run generates approximately 100 gigabytes of raw data, requiring sophisticated software for alignment, variant annotation, and interpretation. Demand is further amplified by clinical adoption. Cloud-based solutions are gaining traction. Additionally, regulatory frameworks such as the FDA’s authorization of bioinformatics software as a medical device (SaMD) have legitimized the sector, encouraging investment. With data generation outpacing human analytical capacity, bioinformatics is no longer ancillary but central to unlocking the value of NGS, positioning it as the most dynamically advancing segment.

By Technology Insights

The Sequencing by Synthesis (SBS) segment remained the dominant technology in the global NGS landscape by holding a substantial share in 2024. Developed and commercialized primarily by Illumina, SBS leverages reversible dye-terminator chemistry to achieve high accuracy and scalability, making it the gold standard for applications requiring precision, such as clinical diagnostics and population genomics. Its dominance is underpinned by unparalleled read accuracy, a critical requirement for regulatory approval of diagnostic assays. In oncology, SBS-based panels like FoundationOne CDx have been FDA-approved for tumor profiling. The technology’s adaptability across applications, from whole-genome to targeted sequencing, further solidifies its position. Additionally, Illumina’s extensive global service network and consumables ecosystem create strong institutional inertia. Despite emerging alternatives, SBS remains entrenched in laboratories worldwide due to its proven performance, regulatory acceptance, and deep integration into research and clinical workflows.

The nanopore sequencing segment is the fastest-growing technology within the Next-Generation Sequencing market, registering a CAGR of 18.3% from 2025 to 2033. This rapid expansion is driven by its unique ability to perform real-time, long-read sequencing without the need for PCR amplification or optical detection. Developed by Oxford Nanopore Technologies, the platform enables direct analysis of native DNA and RNA, preserving epigenetic modifications such as methylation, which are critical in gene regulation studies. The World Health Organization deployed nanopore sequencers during the Ebola outbreak in the Democratic Republic of Congo, achieving on-site viral genome analysis within 48 hours, as documented in The Lancet Infectious Diseases. The portability of devices like the MinION has revolutionized field genomics. The technology’s scalability is also notable running on everything from handheld devices to high-throughput PromethION systems, and it serves both point-of-care and large-scale applications. NASA has even tested nanopore sequencing aboard the International Space Station for microbial monitoring. These attributes—real-time analysis, portability, and epigenetic sensitivity—are propelling nanopore sequencing into new frontiers, making it the most rapidly advancing NGS technology.

By Application Insights

The Sequencing by Synthesis (SBS) segment remained the dominant technology in the global NGS landscape by holding a substantial share in 2024. Developed and commercialized primarily by Illumina, SBS leverages reversible dye-terminator chemistry to achieve high accuracy and scalability, making it the gold standard for applications requiring precision, such as clinical diagnostics and population genomics. Its dominance is underpinned by unparalleled read accuracy, a critical requirement for regulatory approval of diagnostic assays. In oncology, SBS-based panels like FoundationOne CDx have been FDA-approved for tumor profiling. The technology’s adaptability across applications, from whole-genome to targeted sequencing, further solidifies its position. Additionally, Illumina’s extensive global service network and consumables ecosystem create strong institutional inertia. Despite emerging alternatives, SBS remains entrenched in laboratories worldwide due to its proven performance, regulatory acceptance, and deep integration into research and clinical workflows.

The nanopore sequencing segment is the fastest-growing technology within the Next-Generation Sequencing market, registering a CAGR of 18.3% from 2025 to 2033. This rapid expansion is driven by its unique ability to perform real-time, long-read sequencing without the need for PCR amplification or optical detection. Developed by Oxford Nanopore Technologies, the platform enables direct analysis of native DNA and RNA, preserving epigenetic modifications such as methylation, which are critical in gene regulation studies. The World Health Organization deployed nanopore sequencers during the Ebola outbreak in the Democratic Republic of Congo, achieving on-site viral genome analysis within 48 hours, as documented in The Lancet Infectious Diseases. The portability of devices like the MinION has revolutionized field genomics. The technology’s scalability is also notable running on everything from handheld devices to high-throughput PromethION systems, and it serves both point-of-care and large-scale applications. NASA has even tested nanopore sequencing aboard the International Space Station for microbial monitoring. These attributes—real-time analysis, portability, and epigenetic sensitivity—are propelling nanopore sequencing into new frontiers, making it the most rapidly advancing NGS technology.

By Workflow Insights

The sequencing segment held the largest share of the NGS workflow with 64.5% of the total value in 2024. This dominance is due to the capital and operational intensity of the wet-lab phase, which includes sample preparation, library construction, and instrument-based sequencing runs. Each step demands specialized equipment, trained personnel, and high-cost consumables, collectively representing the most resource-heavy stage of the NGS pipeline. According to the U.S. Department of Energy’s Joint Genome Institute, a large share of the budget in large-scale genomics projects is allocated to the sequencing phase, particularly in whole-genome and transcriptomic studies. The reliance on high-throughput platforms, such as Illumina’s NovaSeq, which can process 48 human genomes in a single run, requires substantial investment in infrastructure and maintenance. Additionally, the need for stringent quality control, including fragment size analysis and quantification, adds layers of complexity and cost. Regulatory compliance further amplifies expenditure. Given that data analysis is contingent upon successful sequencing, the upstream phase remains the primary cost center and technological bottleneck, cementing its position as the dominant workflow segment.

The data analysis segment is the fastest-growing component of the NGS workflow and is projected to grow at a CAGR of 16.1% during the coming years. This surge is driven by the exponential increase in data volume and the growing necessity for actionable insights in research and clinical settings. The complexity is further compounded in cancer genomics. Demand for rapid turnaround is intensifying. Cloud-based platforms are gaining adoption. Regulatory recognition is also expanding—the FDA has cleared multiple bioinformatics software packages as SaMD (Software as a Medical Device), including Qiagen’s Clinical Insight, enabling their use in diagnostics. Academic consortia like the Human Cell Atlas rely on machine learning models to interpret single-cell sequencing data. As sequencing becomes more commoditized, the true value is shifting toward interpretation, making data analysis the most dynamically expanding phase of the NGS workflow.

REGIONAL ANALYSIS

North America NGS Market Analysis

North America held the largest share of the global Next-Generation Sequencing market with 41.6% in 2024. The region’s position is anchored in a robust ecosystem of research institutions, biotechnology firms, and federal funding agencies that prioritize genomic innovation. The presence of major NGS platform developers—such as Illumina, Thermo Fisher, and Pacific Biosciences—further strengthens domestic capability. Academic hubs like the Broad Institute and Baylor College of Medicine lead in large-scale sequencing initiatives, including the All of Us Research Program, which aims to sequence one million Americans. Canada complements this momentum with investments in precision health, including the Canadian Personalized Medicine Network, which supports NGS implementation across provinces. With strong intellectual property protection, venture capital funding, and interdisciplinary collaboration, North America remains the epicenter of NGS innovation and commercialization.

Europe NGS Market Analysis

Europe holds a significant market share. The region’s strength lies in its integrated research infrastructure and commitment to public health genomics. The United Kingdom is the regional leader, which has directly influenced NHS diagnostic pathways. Germany follows closely. France has prioritized oncology genomics through its Plan Cancer, mandating NGS testing for all advanced cancer patients. The Netherlands and Sweden are pioneers in population-scale sequencing. Regulatory harmonization through the In Vitro Diagnostic Regulation (IVDR) is streamlining NGS test validation, as noted by the European Diagnostic Manufacturers Association. With strong public funding, ethical governance, and academic excellence, Europe maintains a leading role in advancing both research and clinical applications of NGS.

Asia-Pacific NGS Market Analysis

Asia-Pacific is a lucrative region in the global NGS market. The region’s growth is propelled by rising government investment in life sciences and expanding healthcare infrastructure. China leads the regional market. Japan emphasizes clinical integration. India is rapidly expanding its capabilities. Australia supports NGS through the Australian Genomics Health Alliance, which has implemented genomic testing in major hospitals. With increasing R&D expenditure, growing biotech clusters, and rising awareness of personalized medicine, the Asia-Pacific is poised for sustained growth in the NGS domain.

Latin America NGS Market Analysis

Latin America holds a notable share of the global NGS market. The region’s market is nascent but evolving, with Brazil and Mexico leading in research and clinical adoption. Mexico has expanded NGS in oncology through the National Institute of Genomic Medicine, which provides free sequencing for pediatric cancer patients. Chile and Argentina are developing regional sequencing networks, supported by the Andean Genomics Consortium. Despite constraints, rising academic collaboration and public health demand are fostering gradual expansion, positioning Latin America as an emerging player in the global NGS landscape.

Middle East and Africa NGS Market Analysis

The Middle East and Africa collectively account for a small share of the global NGS market. The region’s development is uneven, with Gulf Cooperation Council (GCC) nations leading in infrastructure investment while sub-Saharan Africa faces significant access barriers. Saudi Arabia is the regional frontrunner. The UAE has established the Centre for Arab Genomic Studies and launched the Emirati Genome Program, sequencing over 20,000 nationals by 2023. In contrast, most African nations lack dedicated sequencing facilities; only South Africa, Nigeria, and Kenya have operational high-throughput labs. South Africa’s National Health Laboratory Service played a pivotal role in identifying the Beta and Omicron SARS-CoV-2 variants. With increasing donor support and regional collaboration, the Middle East and Africa are gradually building genomic capacity, though equitable access remains a long-term challenge.

COMPETITIVE LANDSCAPE

The competitive dynamics of the Next-Generation Sequencing market are defined by a blend of technological differentiation, strategic alliances, and ecosystem dominance. While a few major players control the bulk of the market, the field remains highly contested due to rapid innovation and the expanding scope of genomic applications. Companies are not merely competing on instrument performance but on the completeness of their solutions—encompassing hardware, reagents, software, and service support. The race to enable clinical adoption has intensified, with firms aligning their platforms to regulatory standards and healthcare workflows. At the same time, niche innovators are challenging established leaders by introducing disruptive technologies, such as real-time and long-read sequencing, that address unmet needs in complex genomic analysis. Geographic expansion into emerging markets is another battleground, where localization, affordability, and training determine success. Intellectual property plays a crucial role, with patent disputes shaping market access and commercialization timelines. Additionally, the growing importance of data analysis has shifted competition toward bioinformatics integration, with cloud-based platforms and AI-driven interpretation becoming key differentiators. Ultimately, leadership in this market requires more than technical superiority—it demands the ability to translate genomic data into actionable insights across research, medicine, and public health.

Key Market Participants

A few of the major players in the global next-generation sequencing (NGS) market include

• Illumina
• Thermo Fisher Scientific
• Pacific Biosciences
• Macrogen Inc.
• Partek Inc.
• Genomatix Software GmbH
• Perkin Elmer Inc.
• GATC Biotech AG
• Agilent Technologies Inc.
• Biomatters Ltd., BGI (Beijing Genomics Institute)
• Oxford Nanopore Technologies Ltd.
• DNASTAR Inc.
• Knome Inc.
• Qiagen N.V.

Top Players in the Next-Generation Sequencing Market

• Illumina stands as a preeminent force in the global Next-Generation Sequencing landscape, widely recognized for pioneering high-throughput, accurate sequencing technologies that have become foundational in research and clinical genomics. The company has played a transformative role in democratizing genome analysis by consistently advancing the scalability and affordability of sequencing platforms. Its commitment to innovation is reflected in the development of integrated workflows that span sample preparation to data interpretation, enabling seamless adoption across academic, pharmaceutical, and diagnostic settings. Illumina’s influence extends beyond hardware, as it actively shapes industry standards through collaborations with global health initiatives and regulatory bodies. By fostering open scientific exchange and investing in next-generation chemistries, the company continues to set the benchmark for performance, reliability, and accessibility in NGS, solidifying its position as a central architect of modern genomic medicine.
• Thermo Fisher Scientific has established a formidable presence in the NGS market by delivering end-to-end solutions that integrate instrumentation, reagents, and bioinformatics into unified platforms. The company leverages its vast global distribution network and deep expertise in life sciences to provide tailored sequencing workflows for diverse applications, from oncology to microbiology. Its Ion Torrent technology offers an alternative semiconductor-based approach, appealing to laboratories seeking rapid turnaround and targeted sequencing capabilities. Thermo Fisher actively supports clinical adoption by aligning its products with regulatory requirements and partnering with healthcare systems to implement genomic testing. The company also invests heavily in customer education and technical support, ensuring smooth integration of NGS into complex laboratory environments. Through strategic acquisitions and cross-portfolio synergies, Thermo Fisher has positioned itself as a comprehensive solutions provider, bridging the gap between research innovation and practical implementation in both developed and emerging markets.
• Pacific Biosciences has emerged as a critical innovator in long-read sequencing, offering a technological alternative that captures complex genomic regions inaccessible to short-read platforms. The company’s Single Molecule, Real-Time (SMRT) sequencing technology enables the detection of full-length transcripts, structural variants, and epigenetic modifications, providing a more complete picture of genomic architecture. This capability has made PacBio indispensable in applications such as de novo genome assembly, rare disease research, and agricultural genomics. By focusing on accuracy and completeness, the company addresses limitations inherent in other sequencing methods, particularly in repetitive and highly methylated regions. PacBio’s commitment to transparency and scientific collaboration has earned it strong credibility within the academic and regulatory communities. Its technology is increasingly adopted in reference-grade projects and regulatory submissions, where data integrity is paramount. Through continuous refinement of its platforms and chemistry, Pacific Biosciences is redefining the boundaries of what genomic analysis can achieve.

Top Strategies Used by Key Market Participants

• A primary strategy employed by leading players is the development of integrated, end-to-end sequencing ecosystems that combine instruments, consumables, and software into seamless workflows. By offering comprehensive solutions, companies reduce technical barriers for users and enhance customer retention through platform dependency. These ecosystems are designed to minimize interoperability issues and streamline operations, making NGS more accessible to non-specialist laboratories and clinical settings.
• Another key approach is strategic collaboration with academic institutions, government agencies, and healthcare networks to embed their technologies into large-scale genomic initiatives. These partnerships not only validate platform performance but also position the companies as essential enablers of public health and precision medicine programs, fostering long-term adoption and policy-driven demand.
• A third pivotal strategy is investment in next-generation sequencing modalities, including long-read, single-cell, and portable technologies, to diversify product portfolios and capture emerging application areas. By anticipating shifts in research and clinical needs, companies ensure technological leadership and maintain a competitive edge in an evolving landscape where innovation velocity determines market relevance.

Global NGS Market News

• In February 2023, Illumina launched a global initiative to integrate artificial intelligence into its BaseSpace Cloud Suite, enhancing variant interpretation and workflow automation. This advancement is anticipated to accelerate genomic data analysis and improve clinical decision-making capabilities for researchers and healthcare providers.
• In June 2023, Thermo Fisher Scientific partnered with a pan-European biobanking consortium to standardize NGS protocols across 15 national genomics centers. This collaboration is expected to strengthen the company’s footprint in public health genomics and facilitate regulatory harmonization.
• In October 2023, Pacific Biosciences introduced a new chemistry update for its Revio system, significantly improving read accuracy and throughput for human genome sequencing. This enhancement is projected to expand adoption in reference laboratories and precision medicine programs.
• In January 2024, Oxford Nanopore Technologies deployed its portable MinION sequencers in mobile labs across Southeast Asia for real-time pathogen surveillance. This initiative is anticipated to reinforce the company’s role in global infectious disease monitoring and outbreak response.
• In March 2024, BGI Group collaborated with a Middle Eastern government to establish a national genome center focused on hereditary disease research. This partnership is expected to enhance regional genomic capacity and solidify BGI’s presence in emerging markets.

MARKET SEGMENTATION

This research report on the global next-generation sequencing market has been segmented and sub-segmented based on the product, technology, application, and region.

By Product

• Software
• Services

By Technology

• Targeted Re-Sequencing
• Whole Genome Sequencing
• De Novo Sequencing
• Exome Sequencing
• RNA-Seq
• ChIP-Seq
• Methyl-Seq

By Application

• Diagnostics
• Drug Discovery
• Biomarker Discovery
• Personalized Medicine
• Agriculture and Animals Research

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa